Comparison of first-line immunotherapy efficacy between advanced lung squamous cell carcinoma and pulmonary lymphoepithelioma-like carcinoma: A propensity score matching multicenter study.

Autor: Zhou Y; Department of Cardio-Thoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong; The University of Hongkong-ShenZhen Hospital, Shenzhen, 518000, China., Huang J; Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China., Lan J; Department of General Surgery, the People's Hospital of Gaoan City. Gaoan, Jiangxi, China., Hu H; Department of Radiation Therapy, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China., Yuan Z; The Second Clinical Medical College of Guangdong Medical University, Dongguan, Guangdong, China., Dong L; The Second Clinical Medical College of Guangdong Medical University, Dongguan, Guangdong, China., Deng H; Department of Anesthesiology, the Third Xiangya Hospital, Central South University, Chang-sha, Hunan, China., Yue LA; Huafa Community Health Service Center, Shenzhen, Zhuhai, China., Xiao Y; Department of Cardio-Thoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China., Yang X; Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi; School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Jazyk: angličtina
Zdroj: Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Aug; Vol. 19 (4), pp. 1011-1018.
DOI: 10.4103/jcrt.jcrt_2711_22
Abstrakt: Background: Compared with other lung squamous cell carcinomas (LUSC), pulmonary lymphoepithelioma-like carcinoma (pLELC) is closely associated with Epstein-Barr virus (EBV) infections with a unique molecular profile and immune microenvironment. This study was thus established to compare the treatment response and effectiveness of immunotherapy between pLELC and LUSC.
Material and Methods: We enrolled 31 patients with pLELC and 116 with LUSC receiving first-line immunotherapy at three centers in China and compared the treatment response and effectiveness of immunotherapy. Propensity score matching (PSM) was used to balance the differences in baseline data between the two groups.
Results: Before PSM, progression-free survival and overall survival were longer in the pLELC group than in the LUSC group (progression-free survival: hazard ratio (HR), 1.67, 95% CI: 1.05-2.63, P = 0.028; overall survival: HR, 1.90, 95% CI: 1.06-3.40, P = 0.028). This remained unchanged after PSM (progression-free survival: HR, 1.79, 95% CI: 1.02-3.15, P = 0.044; overall survival: HR, 2.20; 95% CI: 1.10-4.37, P = 0.022).
Conclusion: pLELC showed a clinically meaningful survival benefit compared with traditional LUSC following immunotherapy. Subsequent studies should consider the role of the EBV in the tumor immune microenvironment of pLELC.
Databáze: MEDLINE
Externí odkaz: